Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Prolia Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 2026-A

    Specialty Guideline Management Prolia and Biosimilars

    Customize your policy alerts

    Sign up for cvs_caremark Policy 2026-A alerts

    Get alerted when Policy 2026-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs specialty guideline management and prior authorization for Prolia (denosumab) and listed denosumab biosimilars for osteoporosis, glucocorticoid-induced osteoporosis, cancer-therapy-related bone loss, and rheumatoid arthritis when applicable coverage criteria are met.

    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Prolia and Biosimilars
    Policy CodePolicy 2026-A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit documentation of the applicable coverage criteria and prior therapy when requesting authorization for Prolia or a denosumab biosimilar.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10Products referenced
    12 monthsAuthorization period
    20% / 3%High FRAX thresholds
    5Covered indication categories

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    24 months
    Enhanced continuation threshold
    All otherOther indications

    Covered Indications and General Rules

    Postmenopausal osteoporosis

    Authorization of 12 months may be granted when EITHER of the following criteria is met.

    Qualifying pathway

    • Fragility fracture pathway: Member has a history of fragility fractures, such as a low-trauma fracture from force similar to a fall from standing position.
    • Bone density/FRAX and additional-risk pathway

      • Bone density or FRAX criterion

        • Member has a pre-treatment T-score ≤ -2.5.≤ -2.5
        • Member has osteopenia with a high pre-treatment FRAX probability.Osteopenia: pre-treatment T-score between -1 and -2.5; high FRAX probability per Appendix
      • Additional criterion

        • Member has indicators of very high fracture risk, such as advanced age, frailty, glucocorticoid use, a very low T-score, or increased fall risk.Very low T-score ≤ -3
        • Member has had an inadequate response or intolerance to previous injectable osteoporosis therapy, such as zoledronic acid, teriparatide, or abaloparatide.
        • Member has had an inadequate response or intolerance to previous oral bisphosphonate therapy.

    Osteoporosis in men

    Authorization of 12 months may be granted when any of the following criteria is met.

    Qualifying criterion

    • Member has a history of an osteoporotic vertebral or hip fracture.
    • Bone density or FRAX criterion

      • ANY of the following

        • Member has a pre-treatment T-score ≤ -2.5.≤ -2.5
        • Member has osteopenia with a high pre-treatment FRAX probability.Osteopenia: pre-treatment T-score between -1 and -2.5; high FRAX probability per Appendix

    Glucocorticoid-induced osteoporosis

    Authorization of 12 months may be granted when BOTH of the following criteria are met.

    Required criteria

    • Glucocorticoid exposure: Member is currently receiving or will be initiating glucocorticoid therapy at an equivalent prednisone dose of ≥ 2.5 mg/day for ≥ 3 months.≥ 2.5 mg/day for ≥ 3 months
    • Fracture-risk or prior-treatment pathway

      • Member has had an inadequate response or intolerance to previous bisphosphonate therapy.
      • Fracture-risk criterion

        • Member has a history of a fragility fracture, such as a low-trauma fracture from force similar to a fall from standing position.

    Prostate cancer

    Authorization of 12 months may be granted when the following criterion is met.

    Member is receiving androgen deprivation therapy for prostate cancer.

    Breast cancer

    Authorization of 12 months may be granted when the following criterion is met.

    Member is receiving adjuvant aromatase inhibition therapy for breast cancer.

    Rheumatoid arthritis

    Authorization of 12 months may be granted when the following criterion is met.

    Member has rheumatoid arthritis and the requested therapy is intended to inhibit progression of bone erosion.

    All other indications beyond the listed FDA-approved and compendial uses are considered experimental/investigational and not medically necessary.

    Use of Prolia or a denosumab biosimilar for an indication that is not listed as FDA-approved or compendial is considered not medically necessary.

    Clinical Thresholds and Definitions for Review

    Osteoporosis T-score
    ThresholdPre-treatment T-score ≤ -2.5
    Clinical useQualifies as osteoporosis in applicable coverage criteria.
    Applicable pathwaysUsed in postmenopausal osteoporosis, osteoporosis in men, and glucocorticoid-induced osteoporosis criteria.
    Osteopenia T-score
    ThresholdPre-treatment T-score between -1 and -2.5
    Clinical classificationThis range is identified as osteopenia.
    FRAX requirementWhen used in coverage criteria, osteopenia must be accompanied by a high pre-treatment FRAX probability.

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    12-Month Authorization Subject to Criteria

    Initial authorization: Authorization may be granted for 12 months when the applicable indication-specific coverage criteria are met. This includes postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, prostate cancer with ADT, breast cancer receiving adjuvant aromatase inhibition therapy, and rheumatoid arthritis to inhibit bone-erosion progression.

    • Continuation authorization: Authorization may be granted for 12 months for members currently receiving the requested medication through a previously authorized pharmacy or medical benefit.
    • For members with less than 24 months of therapy, there must be no clinically significant adverse events.
    • For members with 24 months or more of therapy, the member must have experienced clinical benefit, such as improvement or stabilization in T-score since the previous bone mass measurement, and must not have experienced adverse effects.
    Step Therapy

    Document Prior Osteoporosis Therapy

    For postmenopausal osteoporosis, document an inadequate response or intolerance to prior osteoporosis therapy when relying on treatment history to support coverage.

    Policy Background

    This policy addresses coverage of Prolia and listed denosumab biosimilars for reducing fracture risk and preserving or improving bone mass. Covered settings include osteoporosis, glucocorticoid-induced osteoporosis, treatment-related bone loss associated with prostate or breast cancer therapy, and inhibition of bone-erosion progression in rheumatoid arthritis when the applicable criteria are met.

    Key Clinical Definitions

    Fragility fracture
    DefinitionA low-trauma fracture resulting from force similar to a fall from a standing position.
    Coverage relevanceA history of fragility fractures is a qualifying pathway for postmenopausal osteoporosis and glucocorticoid-induced osteoporosis.
    Documentation termFragility fracture history may be used as evidence of fracture risk.
    Osteopenia
    DefinitionA pre-treatment T-score between -1 and -2.5.
    FRAX conditionFor applicable coverage pathways, osteopenia must be accompanied by a high pre-treatment FRAX probability.
    Applicable populations

    Initial Therapy by Indication

    Initial therapy: postmenopausal osteoporosis

    Authorization of 12 months may be granted for postmenopausal members with osteoporosis when either qualifying pathway is met.

    Qualifying pathway

    • Fragility fracture pathway: Member has a history of fragility fractures.

      Fragility fracture includes a low-trauma fracture from force similar to a fall from standing position.

    • Bone density/FRAX and additional-risk pathway

      • Bone density or FRAX criterion

        • Member has a pre-treatment T-score ≤ -2.5.≤ -2.5

    Continuation of Prolia or Biosimilar Therapy

    Required Prior Therapies

    StepApplicable populationPrevious therapy requirementResponse requirement
    1
    Postmenopausal osteoporosis
    Previous injectable osteoporosis therapy, such as zoledronic acid, teriparatide, or abaloparatide, OR previous oral bisphosphonate therapy
    Inadequate response or intolerance
    StepApplicable populationPrevious therapy requirementResponse requirement
    1
    Osteoporosis in men
    Previous bisphosphonate therapy
    Inadequate response or intolerance
    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Prolia and Biosimilars
    Policy CodePolicy 2026-A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit documentation of the applicable coverage criteria and prior therapy when requesting authorization for Prolia or a denosumab biosimilar.
    SourceLink
    On This Page
    Covered Indications and General RulesClinical Thresholds and Definitions for ReviewAuthorization, Documentation, and Denial RisksPolicy BackgroundKey Clinical DefinitionsInitial Therapy by IndicationContinuation of Prolia or Biosimilar TherapyRequired Prior Therapies
    Member has had an inadequate response or intolerance to previous bisphosphonate therapy.
    Member has a pre-treatment T-score ≤ -2.5.≤ -2.5
  1. Member has osteopenia with a high pre-treatment FRAX probability.Osteopenia: pre-treatment T-score between -1 and -2.5; high FRAX probability per Appendix
  2. Glucocorticoid exposure
    Prednisone-equivalent dose≥ 2.5 mg per day
    Minimum durationAt least 3 months
    Therapy statusThe member may be currently receiving or initiating glucocorticoid therapy.
    Glucocorticoid FDA indication exposure
    Prednisone-equivalent dose7.5 mg or greater per day
    Expected exposureExpected to remain on glucocorticoids for at least 6 months
    Covered settingGlucocorticoid-induced osteoporosis in men and women at high risk of fracture who are initiating or continuing systemic glucocorticoids.
    High FRAX major osteoporotic fracture probability
    10-year major osteoporotic fracture probability≥ 20%
    Risk toolFRAX (Fracture Risk Assessment Tool)
    High-probability definitionA major osteoporotic fracture probability at or above this threshold is considered high FRAX probability.
    High FRAX hip fracture probability
    10-year hip fracture probability≥ 3%
    Risk toolFRAX (Fracture Risk Assessment Tool)
    High-probability definitionA hip fracture probability at or above this threshold is considered high FRAX probability.
    Very low T-score indicator
    Very low T-score threshold≤ -3
    Risk classificationAn indicator of very high fracture risk
    Other examples of very high riskAdvanced age, frailty, glucocorticoid use, or increased fall risk
    • Qualifying prior injectable therapies include zoledronic acid (Reclast), teriparatide (Forteo), and abaloparatide (Tymlos).
    • An inadequate response or intolerance to previous oral bisphosphonate therapy also qualifies under the applicable postmenopausal osteoporosis criteria.
    Step Therapy

    Prior Bisphosphonate Therapy

    For osteoporosis in men and glucocorticoid-induced osteoporosis, document an inadequate response or intolerance to previous bisphosphonate therapy when using prior treatment history to meet coverage criteria.

    • For osteoporosis in men, inadequate response or intolerance to previous bisphosphonate therapy is one qualifying pathway; other pathways require an osteoporotic vertebral or hip fracture, or qualifying T-score/FRAX risk.
    • For glucocorticoid-induced osteoporosis, the member must be receiving or initiating glucocorticoid therapy equivalent to prednisone ≥ 2.5 mg/day for ≥ 3 months, plus either inadequate response or intolerance to previous bisphosphonate therapy or a qualifying fracture, T-score, or FRAX risk.
    Documentation Required

    Osteoporosis Documentation Required

    For postmenopausal osteoporosis, osteoporosis in men, or glucocorticoid-induced osteoporosis, submit chart notes, medical records, or claims history supporting the diagnosis and treatment history.

    • Document fracture history, pre-treatment T-score, and pre-treatment FRAX probability when applicable.
    • Include previous medications tried and response to therapy when applicable.
    Documentation Required

    Prostate Cancer Documentation

    For prostate cancer-related treatment, submit documentation supporting current androgen deprivation therapy (ADT).

    • Acceptable support includes chart notes, medical record documentation, or claims history.
    • The covered use is treatment-related bone loss in a member receiving ADT for prostate cancer.
    Documentation Required

    Breast Cancer Documentation

    For breast cancer-related treatment, submit documentation supporting adjuvant aromatase inhibition therapy.

    • Acceptable support includes chart notes, medical record documentation, or claims history.
    • The covered use is in postmenopausal members receiving adjuvant aromatase inhibition therapy to maintain or improve bone mineral density and reduce fracture risk.
    Denial Risk

    Noncovered Indication or Unmet Criteria

    Coverage is limited to the stated FDA-approved or compendial indications and requires satisfaction of all applicable approval criteria with no therapy exclusions. Requests for other indications or requests that do not meet the applicable criteria are considered not medically necessary.

    • Covered compendial uses include treatment-related bone loss with prostate cancer and ADT, breast cancer with adjuvant aromatase inhibition therapy, and inhibition of bone-erosion progression in rheumatoid arthritis.
    • All other indications are considered experimental/investigational and not medically necessary.
    • Denial may result when required documentation, indication-specific criteria, prior-treatment requirements, or continuation criteria are not met.
    Denial Risk

    Verify Osteoporosis Risk and Treatment History

    Insufficient osteoporosis risk or treatment history can result in denial. Verify that the member meets the applicable fracture, T-score, FRAX, glucocorticoid-exposure, and prior-treatment requirements before submitting authorization.

    • Postmenopausal osteoporosis requires a history of fragility fracture, or a pre-treatment T-score ≤ -2.5, or osteopenia with high pre-treatment FRAX probability plus a very-high-risk indicator or inadequate response/intolerance to prior injectable or oral therapy.
    • Osteoporosis in men requires an osteoporotic vertebral or hip fracture, a pre-treatment T-score ≤ -2.5 or osteopenia with high pre-treatment FRAX probability, or inadequate response/intolerance to prior bisphosphonate therapy.
    • Glucocorticoid-induced osteoporosis requires current or planned glucocorticoid therapy equivalent to prednisone ≥ 2.5 mg/day for ≥ 3 months, plus the specified fracture, T-score, FRAX, or prior-bisphosphonate treatment pathway.
    Referenced in postmenopausal osteoporosis, osteoporosis in men, and glucocorticoid-induced osteoporosis criteria.
    High FRAX probability
    Major osteoporotic fracture10-year probability ≥ 20%
    Hip fracture10-year probability ≥ 3%
    DefinitionHigh FRAX probability is met when either threshold is reached.
    FRAX glucocorticoid correction
    Correction triggerGlucocorticoid dose greater than 7.5 mg prednisone equivalent per day
    Major osteoporotic fracture adjustmentMultiply the FRAX-generated risk score by 1.15
    Hip fracture adjustmentMultiply the FRAX-generated risk score by 1.2
    Member has osteopenia with a high pre-treatment FRAX probability.Osteopenia: pre-treatment T-score between -1 and -2.5; high FRAX probability per Appendix
  3. Additional risk or prior-treatment criterion

    • Member has indicators of very high fracture risk, such as advanced age, frailty, glucocorticoid use, a very low T-score, or increased fall risk.Very low T-score ≤ -3
    • Member has had an inadequate response or intolerance to previous injectable osteoporosis therapy, such as zoledronic acid, teriparatide, or abaloparatide.
    • Member has had an inadequate response or intolerance to previous oral bisphosphonate therapy.
  4. Initial therapy: osteoporosis in men

    Authorization of 12 months may be granted for male members with osteoporosis when any qualifying criterion is met.

    Qualifying criterion

    • Member has a history of an osteoporotic vertebral or hip fracture.
    • Bone density or FRAX criterion

      • Member has a pre-treatment T-score ≤ -2.5.≤ -2.5
      • Member has osteopenia with a high pre-treatment FRAX probability.Osteopenia: pre-treatment T-score between -1 and -2.5; high FRAX probability per Appendix
    • Member has had an inadequate response or intolerance to previous bisphosphonate therapy.

    Initial therapy: glucocorticoid-induced osteoporosis

    Authorization of 12 months may be granted when both glucocorticoid exposure and a qualifying fracture-risk or prior-treatment pathway are met.

    Required criteria

    • Glucocorticoid exposure: Member is currently receiving or will be initiating glucocorticoid therapy at an equivalent prednisone dose of ≥ 2.5 mg/day for ≥ 3 months.≥ 2.5 mg/day for ≥ 3 months
    • Qualifying fracture-risk or prior-treatment pathway

      • Member has had an inadequate response or intolerance to previous bisphosphonate therapy.
      • Fracture-risk criterion

        • Member has a history of a fragility fracture.

          Fragility fracture includes a low-trauma fracture from force similar to a fall from standing position.

        • Member has a pre-treatment T-score ≤ -2.5.≤ -2.5
        • Member has osteopenia with a high pre-treatment FRAX probability.Osteopenia: pre-treatment T-score between -1 and -2.5; high FRAX probability per Appendix

    Initial therapy: prostate cancer

    Authorization of 12 months may be granted when the following indication-specific criterion is met.

    Member is receiving androgen deprivation therapy for prostate cancer.

    Initial therapy: breast cancer

    Authorization of 12 months may be granted when the following indication-specific criterion is met.

    Member is receiving adjuvant aromatase inhibition therapy for breast cancer.

    Initial therapy: rheumatoid arthritis

    Authorization of 12 months may be granted when the following indication-specific criterion is met.

    Member has rheumatoid arthritis and the requested therapy is intended to inhibit progression of bone erosion.